Manreet Randhawa

Combined ipilimumab and nivolumab first‐line and after BRAF‐targeted therapy in advanced melanoma

Robert M. Mason, Helen Clare Dearden, Bella Nguyen et al. · Pigment Cell & Melanoma Research · 2019 · 62 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

CX-072 (pacmilimab), a Probody<b> ^® </b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Aung Naing, Fiona Thistlethwaite, Elisabeth G.E. de Vries et al. · Journal for ImmunoTherapy of Cancer · 2021 · 39 citations · Full text

Medicine, Oncology, Pharmacology +17

A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.

Elizabeth Ruth Plummer, Rebecca Kristeleit, Elena Cojocaru et al. · Journal of Clinical Oncology · 2019 · 31 citations

Pharmacy, Oncology, Pharmacology +13

Real‐world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma

Sagun Parakh, Manreet Randhawa, Bella Nguyen et al. · Asia-Pacific Journal of Clinical Oncology · 2018 · 23 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report

Manreet Randhawa, Gregory Gaughran, Christine Archer et al. · World Journal of Clinical Oncology · 2019 · 12 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +16